Anonymous
Guest
Anonymous
Guest
GSK is regretting it now:
http://www.fiercevaccines.com/story...g-profit-margin-dive-novartis-fold/2015-05-07
http://www.fiercevaccines.com/story...g-profit-margin-dive-novartis-fold/2015-05-07
They're talking about it on the GSK side of cafepharma, and even nailing it down to where it likely came from:
" They didn't do their HW on what they were getting or checking the financial health and status of multiple projects. What GSK based their projections on was projects/analysis that NVD performed on their own internally through the integration teams. No questioning of what was reported went on from the GSK counterparts. You had too many people on the NVD side of the integration team who were desperate to impress the right people at GSK and have secure jobs that they reported on only rosey good news scenarios. If you're GSK and reading this, I bet I know exactly where the higher than expected cost base came from and I guarentee you it came from Development. Am I right?? Lots of fraud, hidden spend and questionable accounting of costs and approvals. "
They're talking about it on the GSK side of cafepharma, and even nailing it down to where it likely came from:
" They didn't do their HW on what they were getting or checking the financial health and status of multiple projects. What GSK based their projections on was projects/analysis that NVD performed on their own internally through the integration teams. No questioning of what was reported went on from the GSK counterparts. You had too many people on the NVD side of the integration team who were desperate to impress the right people at GSK and have secure jobs that they reported on only rosey good news scenarios. If you're GSK and reading this, I bet I know exactly where the higher than expected cost base came from and I guarentee you it came from Development. Am I right?? Lots of fraud, hidden spend and questionable accounting of costs and approvals. "
They're talking about it on the GSK side of cafepharma, and even nailing it down to where it likely came from:
" They didn't do their HW on what they were getting or checking the financial health and status of multiple projects. What GSK based their projections on was projects/analysis that NVD performed on their own internally through the integration teams. No questioning of what was reported went on from the GSK counterparts. You had too many people on the NVD side of the integration team who were desperate to impress the right people at GSK and have secure jobs that they reported on only rosey good news scenarios. If you're GSK and reading this, I bet I know exactly where the higher than expected cost base came from and I guarentee you it came from Development. Am I right?? Lots of fraud, hidden spend and questionable accounting of costs and approvals. "